Actinogen Medical (ACW) 2022年年度报告「ASX」.pdf

1、Annual Report 2022ContentsContentsWho we are 1Highlights 2The Xanamem Pipeline 3About Xanamem and Cortisol Diseases 4Clinical Trials Program Overview 5Chairs Letter 6Chief Executive Officers Letter 8Vision and Strategy 10Operating&Financial Review 12Board of Directors and Company Secretary 18Executi

2、ve Leadership Team 20Directors Report 22Remuneration Report(Audited)24Auditors Independence Declaration 37Financial Report 38Notes to the Financial Statements 43Directors Declaration 62Independent Auditors Report 63Shareholder Information 67Corporate Directory 69DisclaimerThis Annual Report may cont

3、ain certain forward-looking statements that are not historical facts;are based on subjective estimates,assumptions and qualifications;and relate to circumstances and events that have not taken place and may not take place.Such forward looking statements should be considered“at-risk statements”-not t

4、o be relied upon as they are subject to known and unknown risks,uncertainties and other factors(such as significant business,economic and competitive uncertainties/contingencies and regulatory and clinical development risks,future outcomes and uncertainties)that may lead to actual results being mate

5、rially different from any forward looking statement or the performance expressed or implied by such forward looking statements.You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.Actinogen Medical does not undertake any obligation t

6、o revise such statements to reflect events or any change in circumstances arising after the date hereof,or to reflect the occurrence of or non-occurrence of any future events.Past performance is not a reliable indicator of future performance.Actinogen Medical does not make any guarantee,representati